Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine. “Vanzacaftor-tezacaftor-deutivacaftor was safe and well tolerated and maintained FEV1 percent predicted from elexacaftor/tezacaftor/ivacaftor baseline with further improved CFTR function,” Jordana E. Hoppe, of the University of Colorado School of Medicine and Children’s Hospital Colorado, and colleagues wrote.